Are you wondering about the combination of Acalabrutinib, Venetoclax, and Obinutuzumab as a treatment for CLL? Here's what's known about these medications and how they work together.
Each drug targets CLL in a different way:
- Acalabrutinib (Calquence) — A BTK inhibitor that blocks a protein cancer cells need to grow
- Show Full Answer
Are you wondering about the combination of Acalabrutinib, Venetoclax, and Obinutuzumab as a treatment for CLL? Here's what's known about these medications and how they work together.
Each drug targets CLL in a different way:
- Acalabrutinib (Calquence) — A BTK inhibitor that blocks a protein cancer cells need to grow
- Venetoclax (Venclexta) — A BCL-2 inhibitor that helps trigger the death of leukemia cells
- Obinutuzumab (Gazyva) — A monoclonal antibody that attaches to proteins on the surface of CLL cells to help destroy them The FDA recently approved the combination of Acalabrutinib and Venetoclax as a first-line treatment option for CLL. This is significant because both medications are taken by mouth, meaning treatment can happen at home rather than at an infusion center.
This combination is also given for a fixed duration — up to 14 cycles (just over a year) — rather than indefinitely, which can make planning easier. As with any treatment, there are important risks to be aware of:
- Serious infections — Both acalabrutinib and venetoclax carry warnings about infection risk
- Bleeding — Another noted risk with both drugs
- Tumor lysis syndrome — A rare but serious condition linked to venetoclax, where cancer cells break down too quickly
It's always worth having a detailed conversation with your care team about whether this regimen fits your specific situation and treatment goals.
5 days ago
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
